Text this: In Children and Adolescents (Ages 6-17) With Attention Deficit Hyperactivity Disorder (ADHD), How Does Viloxazine Extended-Release (ER) Compare with Placebo or Other ADHD Medications in Terms of Improving ADHD Symptoms, Adverse Events and Treatment Discontinuation Rates? A Systematic Review